620
Participants
Start Date
June 19, 2025
Primary Completion Date
November 16, 2027
Study Completion Date
December 14, 2027
Placebo
ARM 1
Low Dose PF-07328948
ARM 2
Medium Dose PF-07328948
ARM 3
High Dose PF-07328948
ARM 4
RECRUITING
Amavita Research Services, North Miami Beach
RECRUITING
FWD Clinical Research, Boca Raton
NOT_YET_RECRUITING
Chicago Medical Research, Hazel Crest
RECRUITING
Velocity Clinical Research, Lincoln, Pioneer Heart Institute, Lincoln
NOT_YET_RECRUITING
North Dallas Research Associates, McKinney
RECRUITING
Northwest Houston Heart Center, Tomball
NOT_YET_RECRUITING
Headlands Horizons, LLC dba Headlands Research-Brownsville, Brownsville
NOT_YET_RECRUITING
Valley Regional Medical Center, Brownsville
NOT_YET_RECRUITING
National Heart Institute, Beverly Hills
RECRUITING
Orange County Research Center, Lake Forest
NOT_YET_RECRUITING
Diex Recherche Trois-Rivieres, Trois-Rivières
NOT_YET_RECRUITING
Kasugai Municipal Hospital, Kasugai
NOT_YET_RECRUITING
Seikeikai New Tokyo Heart Clinic, Matsudo
RECRUITING
Sagamihara Kyodo Hospital, Sagamihara
RECRUITING
Yokohama Municipal Citizen's Hospital, Yokohama
NOT_YET_RECRUITING
National Hospital Organization Yokohama Medical Center, Yokohama
NOT_YET_RECRUITING
National Hospital Organization Mie Chuo Medical Center, Tsu
NOT_YET_RECRUITING
National Hospital Organization Sendai Medical Center, Sendai
NOT_YET_RECRUITING
National Hospital Organization Saitama Hospital, Wako
NOT_YET_RECRUITING
National Hospital Organization Tokyo Medical Center, Meguro-Ku
RECRUITING
Teine Keijinkai Hospital, Sapporo
NOT_YET_RECRUITING
NewHeart Watanabe Institute, Suginami
RECRUITING
Sekino Hospital, Toshimaku
NOT_YET_RECRUITING
National Hospital Organization Iwakuni Clinical Center, Iwakuni
Lead Sponsor
Pfizer
INDUSTRY